HUP9901662A2 - Gesztagén és ösztrogén kombinációjából álló kit és eljárás nőnemű emlősök fogamzásának gátlására - Google Patents

Gesztagén és ösztrogén kombinációjából álló kit és eljárás nőnemű emlősök fogamzásának gátlására

Info

Publication number
HUP9901662A2
HUP9901662A2 HU9901662A HUP9901662A HUP9901662A2 HU P9901662 A2 HUP9901662 A2 HU P9901662A2 HU 9901662 A HU9901662 A HU 9901662A HU P9901662 A HUP9901662 A HU P9901662A HU P9901662 A2 HUP9901662 A2 HU P9901662A2
Authority
HU
Hungary
Prior art keywords
combination
days
gestagen
oestrogen
kit
Prior art date
Application number
HU9901662A
Other languages
English (en)
Inventor
Bernd Düsterberg
Jan Endrikat
Pia Reilhac
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of HUP9901662A2 publication Critical patent/HUP9901662A2/hu
Publication of HUP9901662A3 publication Critical patent/HUP9901662A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

A jelen találmány tárgya eljárás nőnemű emlősök főgamzásánakgátlására, amely egy legalább 28 napős, szekvenciális adagőlásból áll:(a) gesztagén adagőlása ővűlációt gátló dózisban legalább 28 napőn át,kőmbinációban (b) természetes ösztrőgén adagőlásával 5-10 napőn át, aszekvenciális, legalább 28 napős adagőlás végén. A találmány kiterjeda fenti főgamzásgátlási eljárásban alkalmazható kitekre is. ŕ
HU9901662A 1995-12-23 1996-12-20 Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen HUP9901662A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19549264A DE19549264A1 (de) 1995-12-23 1995-12-23 Verfahren und Kit zur Kontrazeption

Publications (2)

Publication Number Publication Date
HUP9901662A2 true HUP9901662A2 (hu) 1999-09-28
HUP9901662A3 HUP9901662A3 (en) 1999-11-29

Family

ID=7781724

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901662A HUP9901662A3 (en) 1995-12-23 1996-12-20 Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen

Country Status (23)

Country Link
US (1) US6995149B1 (hu)
EP (1) EP0868188B1 (hu)
JP (1) JP2000502108A (hu)
KR (1) KR19990076685A (hu)
AT (1) ATE244567T1 (hu)
AU (1) AU716249B2 (hu)
BR (1) BR9612207A (hu)
CA (1) CA2241192A1 (hu)
CZ (1) CZ291743B6 (hu)
DE (2) DE19549264A1 (hu)
DK (1) DK0868188T3 (hu)
ES (1) ES2202498T3 (hu)
HU (1) HUP9901662A3 (hu)
IL (1) IL124472A (hu)
IS (1) IS4753A (hu)
MX (1) MX9804395A (hu)
NO (1) NO982902D0 (hu)
NZ (1) NZ330741A (hu)
PL (1) PL187180B1 (hu)
PT (1) PT868188E (hu)
SK (1) SK79298A3 (hu)
UA (1) UA59356C2 (hu)
WO (1) WO1997023228A2 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
CN1270521A (zh) * 1997-09-12 2000-10-18 美国家用产品公司 第一阶段包含孕激素/***并且第二阶段包含孕激素的口服避孕制剂
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102008036825A1 (de) * 2008-08-05 2010-02-11 Aicuris Gmbh & Co. Kg Schwangerschaftsvermeidung durch Gestagene
ES2734510T3 (es) * 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
ES2795455T3 (es) * 2008-10-08 2020-11-23 Agile Therapeutics Inc Suministro transdérmico
US9192614B2 (en) * 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2756222A1 (en) * 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
WO2012096411A1 (ja) * 2011-01-12 2012-07-19 国立大学法人宮崎大学 難治性炎症性腸疾患の予防又は治療方法
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368373A1 (en) 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
NZ311304A (en) * 1995-06-07 1999-03-29 Cygnus Therapeutic Systems Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US6479475B1 (en) * 1996-07-26 2002-11-12 Wyeth Oral contraceptive
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JP2003527820A (ja) * 1998-08-17 2003-09-24 ザ ステート オブ オレゴン アクティング バイ アンド スルー ザ ステート ボード オブ ハイアー エデュケーション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン 概日時計機能及び光周性を制御する遺伝子

Also Published As

Publication number Publication date
NZ330741A (en) 2000-03-27
IL124472A (en) 2001-07-24
WO1997023228A2 (de) 1997-07-03
ES2202498T3 (es) 2004-04-01
JP2000502108A (ja) 2000-02-22
SK79298A3 (en) 2000-06-12
AU1921997A (en) 1997-07-17
AU716249B2 (en) 2000-02-24
ATE244567T1 (de) 2003-07-15
US6995149B1 (en) 2006-02-07
EP0868188A2 (de) 1998-10-07
CA2241192A1 (en) 1997-07-03
DE59610600D1 (de) 2003-08-14
IS4753A (is) 1998-05-22
DE19549264A1 (de) 1997-06-26
PL187180B1 (pl) 2004-05-31
CZ9802000A3 (cs) 1998-11-11
HUP9901662A3 (en) 1999-11-29
KR19990076685A (ko) 1999-10-15
MX9804395A (es) 1998-09-30
PL327182A1 (en) 1998-11-23
UA59356C2 (uk) 2003-09-15
CZ291743B6 (cs) 2003-05-14
EP0868188B1 (de) 2003-07-09
NO982902L (no) 1998-06-22
WO1997023228A3 (de) 1997-08-28
BR9612207A (pt) 1999-07-13
DK0868188T3 (da) 2003-10-06
IL124472A0 (en) 1998-12-06
PT868188E (pt) 2003-11-28
NO982902D0 (no) 1998-06-22

Similar Documents

Publication Publication Date Title
HUP9901662A2 (hu) Gesztagén és ösztrogén kombinációjából álló kit és eljárás nőnemű emlősök fogamzásának gátlására
BG104451A (en) Antiestrogen and progestin-containing peroral contraceptives
AU560487B2 (en) Contraceptive comprising gestodene and ethinylestradiol
NO976067D0 (no) Farmasöytisk kombinasjonspreparat, sett og fremgangsmåte for hormonell prevensjon
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
FI922206A0 (fi) Osmotisk, oral doseringsform foer fertilitets kontroll.
DE69710896D1 (en) Progestogen-anti-progestogen therapien
CY1105276T1 (el) Τριφασικο στοματικο αντισυλληπτικο
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
ATE91410T1 (de) Osmotische dosierungsform.
Glasier Emergency contraception: time for de-regulation?
DK0921804T3 (da) Tofase oral præventionsmetode og kit som indeholder en kombination af progestin og østrogen